Who are Rapport Therapeutics, Inc.'s main suppliers?

Rapport Therapeutics, Inc. (RAPP) key suppliers include: NEUROPACE, NEUROPACE-INC, JANSSEN-PHARMACEUTICAL-NV, Lexicon Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc. and 7 more. View the full supplier network at chainsifter.com/chain/RAPP.

Who are Rapport Therapeutics, Inc.'s major customers?

Rapport Therapeutics, Inc. (RAPP) key customers include: TENACIA-BIOTECHNOLOGY-HONG-KONG-CO-LTD, NeuroPace, Inc., Xenon Pharmaceuticals Inc., EMERGING-GROWTH-COMPANY, LEERINK-PARTNERS-LLC. View the full customer network at chainsifter.com/chain/RAPP.

What sector is Rapport Therapeutics, Inc. in?

Rapport Therapeutics, Inc. (RAPP) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Rapport Therapeutics, Inc. Suppliers, Customers & Supply Chain (RAPP)

12Suppliers

5Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Rapport Therapeutics, Inc. (RAPP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

19Total relationships

3Distinct source URLs

6High confidence

0.765Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Rapport Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
NEUROPACE	NEUROPACE	92%	Pursuant to the payment schedule set out in the NeuroPace SOWs, the Company will pay NeuroPace an aggregate of up to $ 5.8 million over a period of approximately four years in connection with NeuroPa…
NEUROPACE-INC	NEUROPACE-INC	90%	Pursuant to the NeuroPace Agreement and in accordance with statement of work agreements entered into from time to time, NeuroPace provides us with certain services with respect to data from the RNS s…
JANSSEN-PHARMACEUTICAL-NV	JANSSEN-PHARMACEUTICAL-NV	85%	In August 2022, we entered into an option and license agreement with Janssen Pharmaceutical NV, as amended on April 3, 2023, April 18, 2023, May 2, 2023, October 2, 2023, and April 9, 2024 (collectiv…
LXRX	Lexicon Pharmaceuticals, Inc.	72%	Reciprocal relationship from LXRX graph: Reciprocal relationship from RAPP graph: into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances u…
LXRX	Lexicon Pharmaceuticals, Inc.	72%	into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the numb…
NPCE	NeuroPace, Inc.	72%	Reciprocal relationship from NPCE graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from NPCE graph: ody of peer-reviewed publications and scientific research involving our RNS …
PRAX	Praxis Precision Medicines, Inc.	72%	Reciprocal relationship from PRAX graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from PRAX graph: Reciprocal relationship from RAPP graph: into longer-term commercial supply …
PRAX	Praxis Precision Medicines, Inc.	72%	into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the numb…
SUPN	Supernus Pharmaceuticals, Inc.	72%	into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the numb…
SUPN	Supernus Pharmaceuticals, Inc.	72%	Reciprocal relationship from SUPN graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from RAPP graph: into longer-term commercial supply …
XENE	Xenon Pharmaceuticals Inc.	72%	into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the numb…
XENE	Xenon Pharmaceuticals Inc.	72%	Reciprocal relationship from XENE graph: Reciprocal relationship from RAPP graph: into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances u…

Rapport Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
TENACIA-BIOTECHNOLOGY-HONG-KONG-CO-LTD	TENACIA-BIOTECHNOLOGY-HONG-KONG-CO-LTD	90%	The arrangement provides Tenacia with the exclusive rights to develop and commercialize the Company’s product candidate, RAP-219
NPCE	NeuroPace, Inc.	72%	Reciprocal relationship from NPCE graph: ody of peer-reviewed publications and scientific research involving our RNS System. We also engage in direct-to-patient marketing activities including targete…
XENE	Xenon Pharmaceuticals Inc.	72%	Reciprocal relationship from XENE graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from XENE graph: Reciprocal relationship from RAPP graph: Reciprocal relationship from XENE g…
EMERGING-GROWTH-COMPANY	EMERGING-GROWTH-COMPANY	62%	ritical accounting policy below supplements the critical accounting policies discussed in our Annual Report on Form 10-K filed with the SEC on March 10, 2026. 37 Revenue Recognition We recognize reve…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	62%	s, obtain regulatory approvals, manufacture any product on a commercial scale or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful pr…

Rapport Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
RAPP-DEBT	Debt stack $10.8M	90%	Market cache reports total debt of $10.8M.

Rapport Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Rapport Therapeutics, Inc..

Rapport Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
RAPP-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 148 tracked holders.

Rapport Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
NPCE	NeuroPace, Inc.	100.00	1	['customer', 'supplier']
SUPN	Supernus Pharmaceuticals, Inc.	100.00	1	['supplier']
XENE	Xenon Pharmaceuticals Inc.	100.00	1	['customer', 'supplier']
LXRX	Lexicon Pharmaceuticals, Inc.	100.00	1	['supplier']
PRAX	Praxis Precision Medicines, Inc.	100.00	1	['supplier']
ORANY	ORANGE	50.00	2
NAMSW	NewAmsterdam Pharma Co N.V.	50.00	2
BIIB	Biogen Inc.	50.00	2
CAH	Cardinal Health, Inc.	50.00	2
COLL	Collegium Pharmaceutical, Inc.	50.00	2
BMY	Bristol-Myers Squibb Company	50.00	2
ITGR	Integer Holdings Corporation	50.00	2
TKPHF	Takeda Pharmaceutical Company Limited	50.00	2
LIVN	LivaNova PLC	50.00	2
NBIX	Neurocrine Biosciences, Inc.	50.00	2
MDT	Medtronic plc	50.00	2
SGIOF	Shionogi & Co., Ltd.	50.00	2
NMRA	Neumora Therapeutics, Inc.	50.00	2
TMO	Thermo Fisher Scientific Inc.	50.00	2
MCK	McKesson Corporation	50.00	2

Rapport Therapeutics, Inc. Supply Chain